betahistine has been researched along with Central Nervous System Origin Vertigo in 122 studies
Betahistine: A histamine analog and H1 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.
betahistine : An aminoalkylpyridine that is pyridine substituted by a 2-(methylamino)ethyl group at position 2. It acts as a histamine agonist and a vasodilator, and is thought to improve the microcirculation of the labyrinth, resulting in reduced endolymphatic pressure. It is used (generally as the hydrochloride or mesylate salt) to reduce the symptoms of vertigo, tinnitus, and hearing loss associated with Meniere's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of modified-release (MR) betahistine (48 mg once daily) versus betaserc (24 mg twice daily) in patients with Meniere's disease or vestibular vertigo." | 9.34 | [A study of the efficacy and safety of a new modified-release betahistine formulation in the treatment of vestibular vertigo and Meniere's disease]. ( Kazei, DV; Nauta, J; Parfenov, VA; Zamergrad, MV, 2020) |
| "To compare the efficacy of cinnarizine/betahistine combination with the respective monotherapies in patients with acute peripheral vertigo (APV)." | 9.30 | Cinnarizine/betahistine combination vs. the respective monotherapies in acute peripheral vertigo: a randomized triple-blind placebo-controlled trial. ( Asadi, P; Majdi, A; Naseri Alavi, SA; Vatanparast, K; Zia Ziabari, SM, 2019) |
| "The fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg was found to be not only non-inferior, but superior to betahistine 16 mg in the improvement of peripheral vestibular vertigo." | 9.30 | Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferior ( Hahn, A; Kunelskaya, N; Medzhidieva, D; Paschinin, A; Ryazantsev, SV; Scholtz, AW; Schumacher, K; Stefflova, B; Weisshaar, G, 2019) |
| "The findings of the present meta-analysis indicate that the fixed combination of cinnarizine and dimenhydrinate is a safe and potentially superior treatment option for patients suffering from central and/or peripheral vestibular vertigo, as compared to current standard treatments such as cinnarizine, dimenhydrinate or betahistine given alone in monotherapy." | 9.22 | Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials. ( Hampel, R; Scholtz, AW; Waldfahrer, F; Weisshaar, G, 2022) |
| " One study with a low risk of bias found no significant difference between the betahistine groups and placebo with respect to vertigo after a long-term follow-up period." | 9.22 | Betahistine in Ménière's Disease or Syndrome: A Systematic Review. ( Bruintjes, T; van Benthem, PP; van der Zaag-Loonen, H; Van Esch, B, 2022) |
| "The purpose of this study is to evaluate the effects of betahistine in addition to Epley maneuver on the quality of life of patients with posterior semicircular canal benign paroxysmal positional vertigo (BPPV) of the canalithiasis type." | 9.16 | The effects of betahistine in addition to epley maneuver in posterior canal benign paroxysmal positional vertigo. ( Guneri, EA; Kustutan, O, 2012) |
| "To determine the efficacy of a home-based exercise program by comparing it with betahistine in patients with benign paroxysmal positional vertigo (BPPV)." | 9.13 | Efficacy of a home-based exercise program on benign paroxysmal positional vertigo compared with betahistine. ( Boynukalin, S; Kulcu, DG; Kurtais, Y; Yanik, B, 2008) |
| "42 patients suffering from vertigo were evaluated before and after the treatment with betahistine." | 9.12 | [Assessment of betahistine dihydrochloride effectiveness in the treatment of vertigo of a different aetiology based on videonystagmography test results]. ( Jurkiewicz, D; Kantor, I, 2006) |
| "To evaluate the therapeutic efficacy of Yinxing Damo (YXDM) combined with Betahistine Hydrochloride Injection (BHI) on vertebra basilar artery ischemic vertigo (VBIV)." | 9.11 | [A clinical study on the effect of Yinxing Damo combined with betahistine hydrochloride injection on vertebral basilar artery ischemic vertigo]. ( Deng, GB; Deng, Y; Tan, C; Zhu, HQ, 2005) |
| "The aim of this double-blind, randomized, multicenter study was to compare the efficacy of betahistine dihydrochloride (BH) and flunarizine (FL) using the Dizziness Handicap Inventory (DHI), a validated self-assessment questionnaire that has not previously been used in a clinical trial to evaluate antivertigo drugs." | 9.10 | Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo. ( Albera, R; Ciuffolotti, R; De Benedittis, G; Di Cicco, M; Grazioli, I; Melzi, G; Mira, E; Pallestrini, E; Passali, D; Serra, A; Vicini, C, 2003) |
| "The present study compares the efficacy and safety of betahistine dihydrochloride to that of a placebo in recurrent vertigo resulting from Meniere's disease (MD) or in paroxysmal positional vertigo (PPV) of probable vascular origin." | 9.10 | Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. ( Brizi, S; Fattori, B; Frasconi, P; Ghilardi, L; Guidetti, G; Leprini, M; Maiolino, L; Malannino, N; Mira, E; Mora, R; Nuti, D; Ottoboni, S; Pagnini, P; Pallestrini, E; Passali, D; Russolo, M; Simoncelli, C; Tirelli, G; Vicini, C, 2003) |
| "The effect of betahistine on the vestibulo-ocular reflex (VOR) was assessed in 12 patients suffering from paroxysmal vertigo." | 9.08 | Dose-dependent effect of betahistine on the vestibulo-ocular reflex: a double-blind, placebo controlled study in patients with paroxysmal vertigo. ( Bonink, M; Kingma, H; Konijnenberg, H; Meulenbroeks, A, 1997) |
| "The efficacy of trimetazidine (60 mg/day) in vertigo was compared with that of betahistine (24 mg/day) in a three-month double-blind study." | 9.06 | [Trimetazidine versus betahistine in vestibular vertigo. A double blind study]. ( D'Hooge, D; Kluyskens, P; Lambert, P, 1990) |
| "One hundred and seventeen adult patients suffering from vestibular vertigo were treated in a multicentre double-blind study with flunarizine (10 mg before sleeping) or betahistine dichlorhydrate (8 mg 3 times daily)." | 9.06 | Flunarizine and betahistine. Two different therapeutic approaches in vertigo compared in a double-blind study. ( Elbaz, P, 1988) |
| "A double-blind crossover study was carried out in general practice in 88 patients with peripheral vertigo of unknown origin to compare the efficacy and tolerance of 12 mg betahistine dihydrochloride and 15 mg cinnarizine." | 9.06 | A double-blind crossover study comparing betahistine and cinnarizine in the treatment of recurrent vertigo in patients in general practice. ( Deering, RB; Downey, LJ; Prescott, P; Simmons, RL, 1986) |
| "To assess the effects of betahistine in patients with symptoms of vertigo from different causes." | 8.93 | Betahistine for symptoms of vertigo. ( Hussain, K; Murdin, L; Schilder, AG, 2016) |
| "Clinical studies and meta-analyses demonstrated that betahistine is effective and safe in the treatment of Ménière's disease, BPPV (benign paroxysmal positional vertigo), vestibular neuronitis, and other types of peripheral vertigo." | 8.91 | Use of betahistine in the treatment of peripheral vertigo. ( Cardenas Nuñez, JL; Deschamps, JJ; Ledezma Rodríguez, JG; Liviac Ticse, JA; Navas Romero, A; Ramos Alcocer, R; Rodríguez Montoya, V, 2015) |
| "Betahistine dihydrochloride (betahistine) is currently used in the management of vertigo and vestibular pathologies with different aetiologies." | 8.89 | Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. ( Lacour, M, 2013) |
| " We have focused on betahistine, a structural analogue of histamine with weak histamine H(1) receptor agonist and more potent H(3) receptor antagonist properties, to review the currently available data on the role of the histaminergic system in the recovery process after peripheral vestibular deficits and the effects of histamine analogues in the clinical treatment of vertigo." | 8.81 | Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. ( Lacour, M; Sterkers, O, 2001) |
| "The vasodilating properties of histamine were the basis for histamine treatment of episodic vertigo and other inner ear dysfunctions." | 8.78 | Histamine in the treatment of vertigo. ( Fischer, AJ, 1991) |
| "We will systematically search different databases, including PubMed, EMBASE, Web of Science, the Cochrane Library, Chinese BioMedical Literature Database (CBM), China National Knowledge Infrastructure Database (CNKI), and WanFang to collect the randomised controlled studies that evaluate the efficiency of gastrodin and betahistine in treating patients with vertigo from their inception to November 2020." | 8.02 | Clinical therapeutic effects of gastrodin in combination with betahistine on vertigo: A protocol for systematic review and meta-analysis. ( Jin, S; Liu, F; Qiao, YL; Xiang, WQ, 2021) |
| "The present research was carried out with the objective to establish the clinical effect and safety of betahistine (48 mg daily), for the management of peripheral vestibular vertigo, in patients treated by primary care physicians in Colombia." | 7.96 | Betahistine in the Treatment of Peripheral Vestibular Vertigo: Results of a Real-Life Study in Primary Care. ( Buitrago, D; Castro-Moreno, C; Sanchez-Vanegas, G, 2020) |
| "VIRTUOSO was a prospective, multinational, non-comparative, post-marketing observational programme investigating the effectiveness of betahistine (48 mg/day) and the course of vertigo after the discontinuation of treatment." | 7.85 | Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: The VIRTUOSO study. ( Antonenko, LM; Asaulenko, OI; Golyk, VA; Matsnev, EI; Melnikov, OA; Morozova, SV; Parfenov, VA; Popovych, VI; Sigaleva, EE; Situkho, MI; Zamergrad, MV, 2017) |
| "Study included patients suffering from vertigo, who were prescribed betahistine (48 mg/day) according to local label." | 7.85 | Efficacy of Betahistine by Patient-Reported Outcomes and its Tolerability Profile in Indian Patients with Vestibular Vertigo. ( Biswas, A; Kirtane, MV, 2017) |
| "This subanalysis compared the efficacy of betahistine plus piracetam dual therapy versus betahistine monotherapy using data from OSVaLD, a 3 month, open-label, observational study conducted in 2272 patients with peripheral vestibular vertigo." | 7.81 | Betahistine plus piracetam dual therapy versus betahistine monotherapy for peripheral vestibular vertigo: a confounder-corrected subanalysis of the OSVaLD study. ( Lilenko, SV; Melnikov, OA; Nauta, J; Ouwens, MJ, 2015) |
| "OSVaLD (Observational Study in patients suffering from recurrent peripheral vestibular Vertigo to Assess the effect of betahistine 48 mg/day on quality of Life and Dizziness symptoms) is a 3-month, open-label, multi-national post-marketing surveillance study of betahistine 48 mg/day in the management of patients with vertigo of less than 5 years in duration." | 7.74 | Patient baseline characteristics in an open-label multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD study. ( Benecke, H; Kuessner, D; Pérez-Garrigues, H, 2007) |
| "A study of betahistine (betaserc) in 65 patients aged 59,48 +/- 8,63 years with vertigo in early rehabilitation period of ischemic stroke has been carried out." | 7.73 | [Clinico-neurological and stabilometric analysis of betahistine (betaserc) efficacy in the patients with vertigo in the rehabilitation period of ischemic stroke]. ( Galanov, DV; Gekht, AB; Vialkova, AB, 2005) |
| "A short profile of betahistine and its activity in treatment of Menière's disease and other forms of peripheral vertigo is presented." | 7.71 | Betahistine in the treatment of vertigo. History and clinical implications of recent pharmacological researches. ( Mira, E, 2001) |
| " There was no clear difference regarding efficacy between flunarizine and betahistine in the vertigo study." | 7.69 | Postmarketing study of the use of flunarizine in vestibular vertigo and in migraine. ( Amery, WK; De Locht, P; Verspeelt, J, 1996) |
| "Migrainous vertigo is a common cause of dizziness presenting to an otorhinolaryngology/otoneurology clinic." | 6.79 | Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. ( Amalanathan, S; Augustine, AM; Balraj, A; Lepcha, A; Tyagi, AK, 2014) |
| "Betahistine therapy was also accompanied by progressive, significant improvements in both HADS-A and HADS-D scores (p < 0." | 6.75 | Effects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD study. ( Benecke, H; Bin Sidek, D; D, K; Pérez-Garrigues, H; Sondag, E; Theeuwes, A; Uloziene, I, 2010) |
| "Vertigo is common symptom in clinical practice and among cerebrovascular and otological diseases." | 6.72 | [Clinical effectiveness of betahistine in monotherapy of vertigo for different etiology]. ( Nowak, K; Szymiec, E, 2006) |
| "Vertigo associated with migraine was diagnosed in 25% of the cases." | 6.71 | [Comparative efficacy of betaserc and cinnarizine of vertigo in patients with migraine]. ( Amelin, AV; Gonchar, MA; Nikitin, KA; Skoromets, AA; Tumelevich, BCh, 2003) |
| "Vertebro basilar insufficiency (VBI) is a well known cause of vertigo." | 6.69 | Pre and post betahistine therapy 99m Tc - HMPAO brain spect studies in patients with vertigo. ( Gopinath, G; Kirtane, MV; Krishna, BA; Sangeeta, T, 2000) |
| "To evaluate the efficacy and safety of modified-release (MR) betahistine (48 mg once daily) versus betaserc (24 mg twice daily) in patients with Meniere's disease or vestibular vertigo." | 5.34 | [A study of the efficacy and safety of a new modified-release betahistine formulation in the treatment of vestibular vertigo and Meniere's disease]. ( Kazei, DV; Nauta, J; Parfenov, VA; Zamergrad, MV, 2020) |
| "To compare the efficacy of cinnarizine/betahistine combination with the respective monotherapies in patients with acute peripheral vertigo (APV)." | 5.30 | Cinnarizine/betahistine combination vs. the respective monotherapies in acute peripheral vertigo: a randomized triple-blind placebo-controlled trial. ( Asadi, P; Majdi, A; Naseri Alavi, SA; Vatanparast, K; Zia Ziabari, SM, 2019) |
| "The fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg was found to be not only non-inferior, but superior to betahistine 16 mg in the improvement of peripheral vestibular vertigo." | 5.30 | Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferior ( Hahn, A; Kunelskaya, N; Medzhidieva, D; Paschinin, A; Ryazantsev, SV; Scholtz, AW; Schumacher, K; Stefflova, B; Weisshaar, G, 2019) |
| " One study with a low risk of bias found no significant difference between the betahistine groups and placebo with respect to vertigo after a long-term follow-up period." | 5.22 | Betahistine in Ménière's Disease or Syndrome: A Systematic Review. ( Bruintjes, T; van Benthem, PP; van der Zaag-Loonen, H; Van Esch, B, 2022) |
| "The findings of the present meta-analysis indicate that the fixed combination of cinnarizine and dimenhydrinate is a safe and potentially superior treatment option for patients suffering from central and/or peripheral vestibular vertigo, as compared to current standard treatments such as cinnarizine, dimenhydrinate or betahistine given alone in monotherapy." | 5.22 | Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials. ( Hampel, R; Scholtz, AW; Waldfahrer, F; Weisshaar, G, 2022) |
| "The purpose of this study is to evaluate the effects of betahistine in addition to Epley maneuver on the quality of life of patients with posterior semicircular canal benign paroxysmal positional vertigo (BPPV) of the canalithiasis type." | 5.16 | The effects of betahistine in addition to epley maneuver in posterior canal benign paroxysmal positional vertigo. ( Guneri, EA; Kustutan, O, 2012) |
| "To determine the efficacy of a home-based exercise program by comparing it with betahistine in patients with benign paroxysmal positional vertigo (BPPV)." | 5.13 | Efficacy of a home-based exercise program on benign paroxysmal positional vertigo compared with betahistine. ( Boynukalin, S; Kulcu, DG; Kurtais, Y; Yanik, B, 2008) |
| "42 patients suffering from vertigo were evaluated before and after the treatment with betahistine." | 5.12 | [Assessment of betahistine dihydrochloride effectiveness in the treatment of vertigo of a different aetiology based on videonystagmography test results]. ( Jurkiewicz, D; Kantor, I, 2006) |
| "To evaluate the therapeutic efficacy of Yinxing Damo (YXDM) combined with Betahistine Hydrochloride Injection (BHI) on vertebra basilar artery ischemic vertigo (VBIV)." | 5.11 | [A clinical study on the effect of Yinxing Damo combined with betahistine hydrochloride injection on vertebral basilar artery ischemic vertigo]. ( Deng, GB; Deng, Y; Tan, C; Zhu, HQ, 2005) |
| "The present study compares the efficacy and safety of betahistine dihydrochloride to that of a placebo in recurrent vertigo resulting from Meniere's disease (MD) or in paroxysmal positional vertigo (PPV) of probable vascular origin." | 5.10 | Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. ( Brizi, S; Fattori, B; Frasconi, P; Ghilardi, L; Guidetti, G; Leprini, M; Maiolino, L; Malannino, N; Mira, E; Mora, R; Nuti, D; Ottoboni, S; Pagnini, P; Pallestrini, E; Passali, D; Russolo, M; Simoncelli, C; Tirelli, G; Vicini, C, 2003) |
| "The aim of this double-blind, randomized, multicenter study was to compare the efficacy of betahistine dihydrochloride (BH) and flunarizine (FL) using the Dizziness Handicap Inventory (DHI), a validated self-assessment questionnaire that has not previously been used in a clinical trial to evaluate antivertigo drugs." | 5.10 | Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo. ( Albera, R; Ciuffolotti, R; De Benedittis, G; Di Cicco, M; Grazioli, I; Melzi, G; Mira, E; Pallestrini, E; Passali, D; Serra, A; Vicini, C, 2003) |
| "In a randomized, double-blind clinical study, we evaluated the efficacy and tolerability of the fixed combination of cinnarizine, 20 mg, and dimenhydrinate, 40 mg (Arlevert [ARL]) in comparison to betahistine dimesylate (12 mg) in 82 patients suffering from Ménière's disease for at least 3 months and showing the characteristic triad of symptoms (paroxysmal vertigo attacks, cochlear hearing loss, and tinnitus)." | 5.10 | Fixed combination of cinnarizine and dimenhydrinate versus betahistine dimesylate in the treatment of Ménière's disease: a randomized, double-blind, parallel group clinical study. ( Kostrica, R; Novotný, M, 2002) |
| "To compare the efficacy and safety of a homeopathic remedy (Vertigoheel, Heel Inc, Albuquerque, NM) vs betahistine hydrochloride (active control) in the treatment of patients with vertigo of various origins in a confirmative equivalence trial." | 5.08 | Homeopathic vs conventional treatment of vertigo: a randomized double-blind controlled clinical study. ( Klein, P; Strösser, W; Weiser, M, 1998) |
| "The effect of betahistine on the vestibulo-ocular reflex (VOR) was assessed in 12 patients suffering from paroxysmal vertigo." | 5.08 | Dose-dependent effect of betahistine on the vestibulo-ocular reflex: a double-blind, placebo controlled study in patients with paroxysmal vertigo. ( Bonink, M; Kingma, H; Konijnenberg, H; Meulenbroeks, A, 1997) |
| "The efficacy of trimetazidine (60 mg/day) in vertigo was compared with that of betahistine (24 mg/day) in a three-month double-blind study." | 5.06 | [Trimetazidine versus betahistine in vestibular vertigo. A double blind study]. ( D'Hooge, D; Kluyskens, P; Lambert, P, 1990) |
| "A double-blind crossover study was carried out in general practice in 88 patients with peripheral vertigo of unknown origin to compare the efficacy and tolerance of 12 mg betahistine dihydrochloride and 15 mg cinnarizine." | 5.06 | A double-blind crossover study comparing betahistine and cinnarizine in the treatment of recurrent vertigo in patients in general practice. ( Deering, RB; Downey, LJ; Prescott, P; Simmons, RL, 1986) |
| "One hundred and seventeen adult patients suffering from vestibular vertigo were treated in a multicentre double-blind study with flunarizine (10 mg before sleeping) or betahistine dichlorhydrate (8 mg 3 times daily)." | 5.06 | Flunarizine and betahistine. Two different therapeutic approaches in vertigo compared in a double-blind study. ( Elbaz, P, 1988) |
| " We concluded betahistine might reduce the number of attacks, vertigo intensity and lead to a symptomatic improvement according to global judgement in patients with Menieres disease, but the certainty of evidence is low." | 4.95 | Is betahistine effective for Ménières disease? ( Rosenbaum, A; Winter, M, 2017) |
| "To assess the effects of betahistine in patients with symptoms of vertigo from different causes." | 4.93 | Betahistine for symptoms of vertigo. ( Hussain, K; Murdin, L; Schilder, AG, 2016) |
| "Clinical studies and meta-analyses demonstrated that betahistine is effective and safe in the treatment of Ménière's disease, BPPV (benign paroxysmal positional vertigo), vestibular neuronitis, and other types of peripheral vertigo." | 4.91 | Use of betahistine in the treatment of peripheral vertigo. ( Cardenas Nuñez, JL; Deschamps, JJ; Ledezma Rodríguez, JG; Liviac Ticse, JA; Navas Romero, A; Ramos Alcocer, R; Rodríguez Montoya, V, 2015) |
| "Betahistine dihydrochloride (betahistine) is currently used in the management of vertigo and vestibular pathologies with different aetiologies." | 4.89 | Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. ( Lacour, M, 2013) |
| " This paper presents the results of a meta-analysis of four recent clinical trials evaluating the homeopathic preparation Vertigoheel (VH) compared with usual therapies (betahistine, Ginkgo biloba extract, dimenhydrinate) for vertigo in a total of 1388 patients." | 4.82 | Treatment of vertigo with a homeopathic complex remedy compared with usual treatments: a meta-analysis of clinical trials. ( Klein, P; Schneider, B; Weiser, M, 2005) |
| " We have focused on betahistine, a structural analogue of histamine with weak histamine H(1) receptor agonist and more potent H(3) receptor antagonist properties, to review the currently available data on the role of the histaminergic system in the recovery process after peripheral vestibular deficits and the effects of histamine analogues in the clinical treatment of vertigo." | 4.81 | Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. ( Lacour, M; Sterkers, O, 2001) |
| "The vasodilating properties of histamine were the basis for histamine treatment of episodic vertigo and other inner ear dysfunctions." | 4.78 | Histamine in the treatment of vertigo. ( Fischer, AJ, 1991) |
| "To elucidate the relationship between vertigo and EH volume after medical treatment, we investigated changes in endolymphatic hydrops (EH) volume using inner ear magnetic resonance imaging (ieMRI) in relation to clinical results for vertigo and hearing after administration of the anti-vertiginous medications betahistine, adenosine triphosphate (ATP), isosorbide (ISO), and saireito (SAI) for Meniere's disease (MD)." | 4.31 | Evaluation of changes in endolymphatic hydrops volume after medical treatments for Meniere's disease using 3D magnetic resonance imaging. ( Fujita, H; Inui, H; Kitahara, T; Sakagami, M; Ueda, K; Yamashita, A, 2023) |
| "We will systematically search different databases, including PubMed, EMBASE, Web of Science, the Cochrane Library, Chinese BioMedical Literature Database (CBM), China National Knowledge Infrastructure Database (CNKI), and WanFang to collect the randomised controlled studies that evaluate the efficiency of gastrodin and betahistine in treating patients with vertigo from their inception to November 2020." | 4.02 | Clinical therapeutic effects of gastrodin in combination with betahistine on vertigo: A protocol for systematic review and meta-analysis. ( Jin, S; Liu, F; Qiao, YL; Xiang, WQ, 2021) |
| "The present research was carried out with the objective to establish the clinical effect and safety of betahistine (48 mg daily), for the management of peripheral vestibular vertigo, in patients treated by primary care physicians in Colombia." | 3.96 | Betahistine in the Treatment of Peripheral Vestibular Vertigo: Results of a Real-Life Study in Primary Care. ( Buitrago, D; Castro-Moreno, C; Sanchez-Vanegas, G, 2020) |
| " 99%), metabolized by monoamine oxidases (MAO), the benefits of a high-dosage betahistine monotherapy were compared with those of a lower dosage of betahistine in combination with the MAO-B inhibitor (MAO-B) selegiline on the frequency of acute attacks of vertigo in patients with Menière's disease (MD)." | 3.88 | Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study. ( Kraus, L; Rujescu, D; Schautzer, F; Strupp, M, 2018) |
| "VIRTUOSO was a prospective, multinational, non-comparative, post-marketing observational programme investigating the effectiveness of betahistine (48 mg/day) and the course of vertigo after the discontinuation of treatment." | 3.85 | Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: The VIRTUOSO study. ( Antonenko, LM; Asaulenko, OI; Golyk, VA; Matsnev, EI; Melnikov, OA; Morozova, SV; Parfenov, VA; Popovych, VI; Sigaleva, EE; Situkho, MI; Zamergrad, MV, 2017) |
| "Study included patients suffering from vertigo, who were prescribed betahistine (48 mg/day) according to local label." | 3.85 | Efficacy of Betahistine by Patient-Reported Outcomes and its Tolerability Profile in Indian Patients with Vestibular Vertigo. ( Biswas, A; Kirtane, MV, 2017) |
| "This subanalysis compared the efficacy of betahistine plus piracetam dual therapy versus betahistine monotherapy using data from OSVaLD, a 3 month, open-label, observational study conducted in 2272 patients with peripheral vestibular vertigo." | 3.81 | Betahistine plus piracetam dual therapy versus betahistine monotherapy for peripheral vestibular vertigo: a confounder-corrected subanalysis of the OSVaLD study. ( Lilenko, SV; Melnikov, OA; Nauta, J; Ouwens, MJ, 2015) |
| "OSVaLD (Observational Study in patients suffering from recurrent peripheral vestibular Vertigo to Assess the effect of betahistine 48 mg/day on quality of Life and Dizziness symptoms) is a 3-month, open-label, multi-national post-marketing surveillance study of betahistine 48 mg/day in the management of patients with vertigo of less than 5 years in duration." | 3.74 | Patient baseline characteristics in an open-label multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD study. ( Benecke, H; Kuessner, D; Pérez-Garrigues, H, 2007) |
| " The aim of our work was to analyze effectiveness of betahistine hydrochloride (Betaserc) treatment on vertigo, nausea, vomiting, tinnitus and progressive hearing loss basing on the medical assessment (interview) performed by doctors and patient's personal questionnaires as well as to collect and accumulate data about balance system disorders." | 3.73 | [Assessment of betahistine dihydrochloride effectiveness in the treatment of disturbance of balance system, based on analysis of doctors and patients questionnaires results]. ( Jurkiewicz, D; Kantor, I; Usowski, J, 2006) |
| "Betahistine is a structural analogue of histamine that is prescribed for the treatment of vestibular disorders such as Ménière's disease and the symptomatic treatment of vertigo." | 3.73 | Betahistine: a retrospective synopsis of safety data. ( Jeck-Thole, S; Wagner, W, 2006) |
| "A study of betahistine (betaserc) in 65 patients aged 59,48 +/- 8,63 years with vertigo in early rehabilitation period of ischemic stroke has been carried out." | 3.73 | [Clinico-neurological and stabilometric analysis of betahistine (betaserc) efficacy in the patients with vertigo in the rehabilitation period of ischemic stroke]. ( Galanov, DV; Gekht, AB; Vialkova, AB, 2005) |
| "A short profile of betahistine and its activity in treatment of Menière's disease and other forms of peripheral vertigo is presented." | 3.71 | Betahistine in the treatment of vertigo. History and clinical implications of recent pharmacological researches. ( Mira, E, 2001) |
| " There was no clear difference regarding efficacy between flunarizine and betahistine in the vertigo study." | 3.69 | Postmarketing study of the use of flunarizine in vestibular vertigo and in migraine. ( Amery, WK; De Locht, P; Verspeelt, J, 1996) |
| "Tandem Romberg test (TRT) for primary efficacy, standing on foam, tandem gait, subjective visual vertical and spontaneous nystagmus for secondary efficacy, Vestibular Rehabilitation Benefit Questionnaire (VRBQ) for exploratory efficacy; nasal symptoms and adverse events for safety." | 3.30 | Efficacy and Safety of Intranasal Betahistine in the Treatment of Surgery-Induced Acute Vestibular Syndrome: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Study. ( Betka, J; Chovanec, M; Devèze, A; Giannuzzi, AL; Krempaská, S; Meyer, T; Przewoźny, T; Scheich, M; Strupp, M; Van de Heyning, P; Van Rompaey, V, 2023) |
| "Migrainous vertigo is a common cause of dizziness presenting to an otorhinolaryngology/otoneurology clinic." | 2.79 | Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. ( Amalanathan, S; Augustine, AM; Balraj, A; Lepcha, A; Tyagi, AK, 2014) |
| "Betahistine therapy was also accompanied by progressive, significant improvements in both HADS-A and HADS-D scores (p < 0." | 2.75 | Effects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD study. ( Benecke, H; Bin Sidek, D; D, K; Pérez-Garrigues, H; Sondag, E; Theeuwes, A; Uloziene, I, 2010) |
| "Vertigo is common symptom in clinical practice and among cerebrovascular and otological diseases." | 2.72 | [Clinical effectiveness of betahistine in monotherapy of vertigo for different etiology]. ( Nowak, K; Szymiec, E, 2006) |
| "Vertigo associated with migraine was diagnosed in 25% of the cases." | 2.71 | [Comparative efficacy of betaserc and cinnarizine of vertigo in patients with migraine]. ( Amelin, AV; Gonchar, MA; Nikitin, KA; Skoromets, AA; Tumelevich, BCh, 2003) |
| "Vertebro basilar insufficiency (VBI) is a well known cause of vertigo." | 2.69 | Pre and post betahistine therapy 99m Tc - HMPAO brain spect studies in patients with vertigo. ( Gopinath, G; Kirtane, MV; Krishna, BA; Sangeeta, T, 2000) |
| "Vertigo was the most responsive symptom." | 2.64 | Betahistine hydrochloride in Méniére's disease. ( Frew, IJ; Menon, GN, 1976) |
| " Betahistidine was given in an average dosage of 4 mg three times daily." | 2.64 | [Betahistidine hydrochloride in the treatment of vertebro-basilar insufficiency]. ( Botez, MI, 1975) |
| "Vertigo is associated with a wide range of vestibular pathologies." | 2.61 | Management of peripheral vertigo with antihistamines: New options on the horizon. ( Attali, P; Dyhrfjeld-Johnsen, J, 2019) |
| "MD subjects with and without migraine demonstrated a decrease in both vertigo spells and migrainous attacks during combined therapy (from 9." | 2.50 | Association of cinnarizine and betahistine in prophylactic therapy for Ménière's disease with and without migraine. ( Benazzo, M; Bussi, M; Gatti, O; Quaglieri, S; Sykopetrites, V; Teggi, R, 2014) |
| "Dizziness is not a unique clinical picture, but rather is the unspecific symptom of numerous diseases." | 2.44 | [Frequently occurring forms of dizziness and their treatment]. ( Thömke, F, 2007) |
| "Vertigo is a very frequent disorder, associated with highly disabling symptomatology." | 2.43 | Betahistine in the treatment of vertiginous syndromes: a meta-analysis. ( Della Pepa, C; Eandi, M; Guidetti, G, 2006) |
| "Gastrodine injection was the most commonly used traditional Chinese medicin in clinical to treat vertigo diserse, the therapeutic regimen combining with traditional Chinese and western medicine has more advantages." | 1.40 | [Characteristics and drug analysis associated with vertigo disease in real world]. ( Li, YY; Wang, YY; Xie, Q; Xie, YM; Yang, W; Zhao, W; Zhuang, Y, 2014) |
| "Vertigo was caused by chronic brain ischemia in 17 cases and by the disturbance of blood circulation in the vertebral-basilar system in 14 patients with osteochondrosis of cervical spine." | 1.38 | [Treatment of vestibular vertigo and Ménière syndrome in outpatient clinics]. ( Boĭko, AN; Ganzhula, PA; Khozova, AA; Kostenko, EV; Lebedeva, AV; Lisenker, LN; Otcheskaia, OV; Petrova, LV; Torgovanova, EA, 2012) |
| "Vestibular neuritis is a group of symptoms resulting from a sudden unilateral vestibular dysfunction." | 1.34 | [Vestibular neuritis--a case description]. ( Bujak, K; Kasacka, I, 2007) |
| " High efficacy of betaserk used during 2 months in dosage 16 mg three times a day was demonstrated by improvement of the patient's state in 97% cases." | 1.33 | [Epidemiology, clinical features and betaserc therapy of vertigo in initial and reversible cerebrovascular pathology]. ( Alekseeva, NS; Chechetkin, AO; Fedin, PA; Gornostaeva, GV; Prokopovich, ME; Varakin, IuIa, 2005) |
| "Vestibular vertigo is a primary symptom in neurootological clinical practice and is common among cerebrovascular diseases." | 1.32 | Investigation of Betaserc in auditory and vestibular disturbances. ( Datcov, E; Petrova, D; Sachansca, T, 2004) |
| "Trimetazidine was found to be significantly more effective than betahistine as far as the overall evolution of the ENT disease was concerned, yielding 79% and 57% improvement rates in each group, respectively (p = 0." | 1.28 | [Trimetazidine versus betahistine in Ménière's disease. A double blind method]. ( De Domenico, F; Martini, A, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (20.49) | 18.7374 |
| 1990's | 13 (10.66) | 18.2507 |
| 2000's | 36 (29.51) | 29.6817 |
| 2010's | 33 (27.05) | 24.3611 |
| 2020's | 15 (12.30) | 2.80 |
| Authors | Studies |
|---|---|
| Scholtz, AW | 3 |
| Waldfahrer, F | 1 |
| Hampel, R | 1 |
| Weisshaar, G | 3 |
| Webster, KE | 1 |
| Galbraith, K | 1 |
| Harrington-Benton, NA | 1 |
| Judd, O | 1 |
| Kaski, D | 1 |
| Maarsingh, OR | 1 |
| MacKeith, S | 1 |
| Ray, J | 1 |
| Van Vugt, VA | 1 |
| Burton, MJ | 1 |
| Yamashita, A | 2 |
| Kitahara, T | 2 |
| Sakagami, M | 2 |
| Ueda, K | 1 |
| Fujita, H | 1 |
| Inui, H | 1 |
| Van de Heyning, P | 1 |
| Betka, J | 1 |
| Chovanec, M | 1 |
| Devèze, A | 1 |
| Giannuzzi, AL | 1 |
| Krempaská, S | 1 |
| Przewoźny, T | 1 |
| Scheich, M | 1 |
| Strupp, M | 3 |
| Van Rompaey, V | 1 |
| Meyer, T | 1 |
| Asadi, P | 1 |
| Zia Ziabari, SM | 1 |
| Majdi, A | 2 |
| Vatanparast, K | 1 |
| Naseri Alavi, SA | 2 |
| Hahn, A | 1 |
| Stefflova, B | 1 |
| Medzhidieva, D | 1 |
| Ryazantsev, SV | 1 |
| Paschinin, A | 1 |
| Kunelskaya, N | 1 |
| Schumacher, K | 1 |
| Molnár, A | 2 |
| Maihoub, S | 2 |
| Tamás, L | 2 |
| Szirmai, Á | 2 |
| Naples, JG | 1 |
| Amini, K | 1 |
| Taghizadeh-Ghehi, M | 1 |
| Espinosa-Sanchez, JM | 1 |
| Lopez-Escamez, JA | 1 |
| Parfenov, VA | 2 |
| Zamergrad, MV | 2 |
| Kazei, DV | 1 |
| Nauta, J | 2 |
| Qiao, YL | 1 |
| Xiang, WQ | 1 |
| Liu, F | 1 |
| Jin, S | 1 |
| Van Esch, B | 1 |
| van der Zaag-Loonen, H | 1 |
| Bruintjes, T | 1 |
| van Benthem, PP | 1 |
| López-Blanco, R | 1 |
| Guerrero-Molina, MP | 1 |
| González-de la Aleja, J | 1 |
| Ruiz-Morales, J | 1 |
| Golyk, VA | 1 |
| Matsnev, EI | 1 |
| Morozova, SV | 2 |
| Melnikov, OA | 2 |
| Antonenko, LM | 1 |
| Sigaleva, EE | 1 |
| Situkho, MI | 1 |
| Asaulenko, OI | 1 |
| Popovych, VI | 1 |
| Kirtane, MV | 2 |
| Biswas, A | 1 |
| Bruderer, SG | 1 |
| Bodmer, D | 1 |
| Stohler, NA | 1 |
| Jick, SS | 1 |
| Meier, CR | 1 |
| Rosenbaum, A | 1 |
| Winter, M | 1 |
| Kraus, L | 1 |
| Schautzer, F | 1 |
| Rujescu, D | 1 |
| Xue, H | 1 |
| Xiang, W | 1 |
| Yu, Y | 1 |
| Liu, G | 1 |
| Chong, Y | 1 |
| Zhou, J | 1 |
| Yuan, Q | 1 |
| Liu, DL | 1 |
| Yu, LS | 1 |
| Zhang, QF | 1 |
| Ward, B | 1 |
| Wettstein, V | 1 |
| Golding, J | 1 |
| Corallo, G | 1 |
| Nuti, D | 2 |
| Trabalzini, F | 1 |
| Mandala, M | 1 |
| Sanchez-Vanegas, G | 1 |
| Castro-Moreno, C | 1 |
| Buitrago, D | 1 |
| Dyhrfjeld-Johnsen, J | 1 |
| Attali, P | 1 |
| Wu, V | 1 |
| Sykes, EA | 1 |
| Beyea, MM | 1 |
| Simpson, MTW | 1 |
| Beyea, JA | 1 |
| Lepcha, A | 1 |
| Amalanathan, S | 1 |
| Augustine, AM | 1 |
| Tyagi, AK | 1 |
| Balraj, A | 1 |
| Lacour, M | 2 |
| Xie, Q | 1 |
| Li, YY | 1 |
| Xie, YM | 1 |
| Yang, W | 1 |
| Zhao, W | 1 |
| Zhuang, Y | 1 |
| Wang, YY | 1 |
| Teggi, R | 1 |
| Gatti, O | 1 |
| Sykopetrites, V | 1 |
| Quaglieri, S | 1 |
| Benazzo, M | 1 |
| Bussi, M | 1 |
| Lilenko, SV | 1 |
| Ouwens, MJ | 1 |
| Ramos Alcocer, R | 1 |
| Ledezma Rodríguez, JG | 1 |
| Navas Romero, A | 1 |
| Cardenas Nuñez, JL | 1 |
| Rodríguez Montoya, V | 1 |
| Deschamps, JJ | 1 |
| Liviac Ticse, JA | 1 |
| Adrion, C | 2 |
| Fischer, CS | 1 |
| Wagner, J | 1 |
| Gürkov, R | 2 |
| Mansmann, U | 2 |
| Yi, C | 1 |
| Wenping, X | 1 |
| Hui, X | 1 |
| Xin, H | 1 |
| Xiue, L | 1 |
| Jun, Z | 1 |
| Shangyong, G | 1 |
| Murdin, L | 1 |
| Hussain, K | 1 |
| Schilder, AG | 1 |
| Okamoto, H | 1 |
| Fukushima, M | 1 |
| Ito, T | 1 |
| Ota, I | 1 |
| Yamanaka, T | 1 |
| Pommer, P | 1 |
| Olszewski, J | 1 |
| Repetowski, M | 1 |
| Kuśmierczyk, K | 1 |
| Otto, V | 1 |
| Fischer, B | 1 |
| Schwarz, M | 1 |
| Baumann, W | 1 |
| Preibisch-Effenberger, R | 1 |
| Kulcu, DG | 1 |
| Yanik, B | 1 |
| Boynukalin, S | 1 |
| Kurtais, Y | 1 |
| James, AL | 1 |
| Thorp, MA | 1 |
| Stambolieva, K | 1 |
| Angov, G | 1 |
| Benecke, H | 2 |
| Pérez-Garrigues, H | 2 |
| Bin Sidek, D | 1 |
| Uloziene, I | 1 |
| D, K | 1 |
| Sondag, E | 1 |
| Theeuwes, A | 1 |
| Guneri, EA | 1 |
| Kustutan, O | 1 |
| Filipe Mingas, LB | 1 |
| Rader, T | 1 |
| Louza, J | 1 |
| Olzowy, B | 1 |
| Krause, E | 1 |
| Maslovara, S | 1 |
| Soldo, SB | 1 |
| Puksec, M | 1 |
| Balaban, B | 1 |
| Penavic, IP | 1 |
| Vasyl'chuk, IS | 1 |
| Kozlova, OO | 1 |
| Trinus, KF | 1 |
| Holovchenko, IuI | 1 |
| Slobodin, TM | 1 |
| Kostenko, EV | 1 |
| Petrova, LV | 1 |
| Torgovanova, EA | 1 |
| Ganzhula, PA | 1 |
| Lisenker, LN | 1 |
| Otcheskaia, OV | 1 |
| Khozova, AA | 1 |
| Lebedeva, AV | 1 |
| Boĭko, AN | 1 |
| Golubovskiĭ, OA | 1 |
| Fedorova, OV | 1 |
| Mira, E | 4 |
| Guidetti, G | 2 |
| Ghilardi, L | 1 |
| Fattori, B | 1 |
| Malannino, N | 1 |
| Maiolino, L | 1 |
| Mora, R | 1 |
| Ottoboni, S | 1 |
| Pagnini, P | 1 |
| Leprini, M | 1 |
| Pallestrini, E | 2 |
| Passali, D | 2 |
| Russolo, M | 1 |
| Tirelli, G | 1 |
| Simoncelli, C | 1 |
| Brizi, S | 1 |
| Vicini, C | 2 |
| Frasconi, P | 1 |
| Sampson, WI | 1 |
| Amelin, AV | 1 |
| Skoromets, AA | 1 |
| Gonchar, MA | 1 |
| Tumelevich, BCh | 1 |
| Nikitin, KA | 1 |
| Albera, R | 1 |
| Ciuffolotti, R | 1 |
| Di Cicco, M | 1 |
| De Benedittis, G | 1 |
| Grazioli, I | 1 |
| Melzi, G | 1 |
| Serra, A | 1 |
| Novotný, M | 1 |
| Kostrica, R | 1 |
| Barkhatov, MV | 1 |
| Tepper, EA | 1 |
| Galaktionova, MIu | 1 |
| Zaĭtseva, OV | 1 |
| Solov'eva, AD | 1 |
| Kornilova, LN | 1 |
| Akarachkova, ES | 1 |
| Temnikova, VV | 1 |
| Prokopenko, SV | 1 |
| Rudnev, VA | 1 |
| Afanas'eva, EV | 1 |
| Abramov, VG | 1 |
| Schneider, B | 1 |
| Klein, P | 2 |
| Weiser, M | 2 |
| Petrova, D | 1 |
| Sachansca, T | 1 |
| Datcov, E | 1 |
| Larikova, TI | 1 |
| Cherevikova, GM | 1 |
| Butko, DIu | 1 |
| Cavaliere, M | 1 |
| Mottola, G | 1 |
| Iemma, M | 1 |
| Deng, Y | 1 |
| Zhu, HQ | 1 |
| Deng, GB | 1 |
| Tan, C | 1 |
| Gornostaeva, GV | 1 |
| Varakin, IuIa | 1 |
| Prokopovich, ME | 1 |
| Alekseeva, NS | 1 |
| Fedin, PA | 1 |
| Chechetkin, AO | 1 |
| Helling, K | 1 |
| Scherer, H | 1 |
| Gekht, AB | 1 |
| Vialkova, AB | 1 |
| Galanov, DV | 1 |
| Kantor, I | 2 |
| Jurkiewicz, D | 2 |
| Jeck-Thole, S | 1 |
| Wagner, W | 1 |
| Nowak, K | 1 |
| Szymiec, E | 1 |
| Usowski, J | 1 |
| Thömke, F | 1 |
| Bujak, K | 1 |
| Kasacka, I | 1 |
| Kuessner, D | 1 |
| Della Pepa, C | 1 |
| Eandi, M | 1 |
| Harris, T | 1 |
| Nietsch, P | 1 |
| Oosterveld, WJ | 2 |
| Müller, H | 1 |
| Buttkus, R | 1 |
| Jügelt, E | 1 |
| Shiozawa, A | 1 |
| Ichikawa, Y | 1 |
| Komuro, C | 1 |
| Idzu, G | 1 |
| Ishikawa, M | 1 |
| Kurashige, S | 1 |
| Miyazaki, H | 1 |
| Yamanaka, H | 1 |
| Sakamoto, T | 1 |
| Canty, P | 1 |
| Valentine, J | 1 |
| Petermann, W | 1 |
| Mulch, G | 1 |
| Bandtlow, O | 1 |
| Wang, JJ | 1 |
| Dutia, MB | 1 |
| Fujino, A | 2 |
| Tokumasu, K | 2 |
| Yosio, S | 1 |
| Naganuma, H | 2 |
| Yoneda, S | 2 |
| Nakamura, K | 1 |
| Okamoto, M | 1 |
| Hoshino, I | 1 |
| Arai, M | 1 |
| Verspeelt, J | 1 |
| De Locht, P | 1 |
| Amery, WK | 1 |
| Dereure, O | 1 |
| Guilhou, JJ | 1 |
| Kingma, H | 1 |
| Bonink, M | 1 |
| Meulenbroeks, A | 1 |
| Konijnenberg, H | 1 |
| Strösser, W | 1 |
| Gusev, EI | 1 |
| Nikonov, AA | 1 |
| Skvortsova, VI | 1 |
| Avakian, GN | 1 |
| Gordeeva, TN | 1 |
| Katunina, EA | 1 |
| Ataian, AV | 1 |
| Krishna, BA | 1 |
| Sangeeta, T | 1 |
| Gopinath, G | 1 |
| Mascías, J | 1 |
| Pérez, OS | 1 |
| Chaverri, D | 1 |
| Mora, JS | 1 |
| Sterkers, O | 1 |
| Lumholtz, IB | 2 |
| Chüden, HG | 1 |
| Wilmot, TJ | 1 |
| Menon, GN | 2 |
| Frew, IJ | 1 |
| Botez, MI | 1 |
| Kawabata, A | 1 |
| Sasa, M | 1 |
| Kishimoto, T | 1 |
| Takaori, S | 1 |
| Fischer, AJ | 1 |
| Aantaa, E | 1 |
| Kluyskens, P | 1 |
| Lambert, P | 1 |
| D'Hooge, D | 1 |
| Martini, A | 1 |
| De Domenico, F | 1 |
| Cullen, JR | 1 |
| Hall, SJ | 1 |
| Allen, RH | 1 |
| Elbaz, P | 1 |
| Deering, RB | 1 |
| Prescott, P | 1 |
| Simmons, RL | 1 |
| Downey, LJ | 1 |
| Elia, JC | 1 |
| Hicks, JJ | 1 |
| Hicks, JN | 1 |
| Cooley, HN | 1 |
| Ito, H | 1 |
| Nakajima, M | 1 |
| Takasu, T | 1 |
| Satake, K | 1 |
| Ogino, H | 1 |
| Yamaguchi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of the Administration of L-arginine vs. Placebo on the vHIT Result, Vestibular Caloric Tests and Symptoms of Patients Diagnosed With Presbyvestibulopathy.[NCT05932979] | Phase 2 | 24 participants (Anticipated) | Interventional | 2023-05-02 | Recruiting | ||
| A Pilot Trial of Galcanezumab for Vestibular Migraine[NCT04417361] | Phase 2 | 50 participants (Anticipated) | Interventional | 2020-09-18 | Recruiting | ||
| Reduction of Plasma Vasopressin Level in Patients With Meniere's Disease[NCT01099046] | 200 participants (Anticipated) | Interventional | 2009-01-31 | Recruiting | |||
| Effectiveness of Additional Protocol Exercises for Cervical Mobility and Proprioception in Vestibular Rehabilitation: a Randomized Controlled Trial[NCT02622516] | 28 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for betahistine and Central Nervous System Origin Vertigo
| Article | Year |
|---|---|
Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials.
Topics: Adult; Aged; Betahistine; Cinnarizine; Dimenhydrinate; Double-Blind Method; Female; Humans; Male; Mi | 2022 |
Systemic pharmacological interventions for Ménière's disease.
Topics: Adrenal Cortex Hormones; Adult; Betahistine; Diuretics; Histamine Antagonists; Humans; Meniere Disea | 2023 |
The pharmacological management of vertigo in Meniere disease.
Topics: Adrenal Cortex Hormones; Betahistine; Clinical Trials as Topic; Diuretics; Female; Gentamicins; Huma | 2020 |
Betahistine in Ménière's Disease or Syndrome: A Systematic Review.
Topics: Betahistine; Deafness; Humans; Meniere Disease; Syndrome; Tinnitus; Vertigo | 2022 |
Is betahistine effective for Ménières disease?
Topics: Betahistine; Humans; Meniere Disease; Treatment Outcome; Vasodilator Agents; Vertigo | 2017 |
Management of peripheral vertigo with antihistamines: New options on the horizon.
Topics: Aged; Animals; Azetidines; Betahistine; Histamine Agonists; Histamine Antagonists; Humans; Pyrimidin | 2019 |
Approach to Ménière disease management.
Topics: Betahistine; Diet, Sodium-Restricted; Disease Management; Diuretics; Dizziness; Female; Hearing Loss | 2019 |
Betahistine treatment in managing vertigo and improving vestibular compensation: clarification.
Topics: Animals; Betahistine; Histamine; Humans; Receptors, Histamine; Vertigo; Vestibular Diseases; Vestibu | 2013 |
Association of cinnarizine and betahistine in prophylactic therapy for Ménière's disease with and without migraine.
Topics: Betahistine; Calcium Channel Blockers; Cinnarizine; Drug Therapy, Combination; Female; Follow-Up Stu | 2014 |
Use of betahistine in the treatment of peripheral vertigo.
Topics: Betahistine; Histamine Agonists; Humans; Postural Balance; Quality of Life; Vertigo; Vestibule, Laby | 2015 |
Betahistine for symptoms of vertigo.
Topics: Benign Paroxysmal Positional Vertigo; Betahistine; Humans; Randomized Controlled Trials as Topic; Ve | 2016 |
Menière's disease.
Topics: Acute Disease; Administration, Oral; Betahistine; Hearing Loss; Humans; Incidence; Meniere Disease; | 2007 |
[Rehabilitation of patients with peripheral vestibular disorders].
Topics: Ataxia; Betahistine; Combined Modality Therapy; Exercise Therapy; Histamine Agonists; Humans; Vertig | 2004 |
Treatment of vertigo with a homeopathic complex remedy compared with usual treatments: a meta-analysis of clinical trials.
Topics: Betahistine; Dimenhydrinate; Drug Combinations; Ginkgo biloba; Histamine Agonists; Humans; Materia M | 2005 |
Improving the quality of life in patients with vestibular disorders: the role of medical treatments and physical rehabilitation.
Topics: Betahistine; Histamine Agonists; Humans; Quality of Life; Vertigo; Vestibular Diseases | 2008 |
[Frequently occurring forms of dizziness and their treatment].
Topics: Amines; Anticonvulsants; Betahistine; Carbamazepine; Cyclohexanecarboxylic Acids; Diagnosis, Differe | 2007 |
Betahistine in the treatment of vertiginous syndromes: a meta-analysis.
Topics: Betahistine; Histamine Agonists; Humans; Vertigo | 2006 |
Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action.
Topics: Animals; Betahistine; Histamine; Histamine Agonists; Histamine Antagonists; Humans; Vertigo | 2001 |
Histamine in the treatment of vertigo.
Topics: Animals; Betahistine; Histamine; Humans; Meniere Disease; Receptors, Histamine; Vertigo | 1991 |
43 trials available for betahistine and Central Nervous System Origin Vertigo
| Article | Year |
|---|---|
Efficacy and Safety of Intranasal Betahistine in the Treatment of Surgery-Induced Acute Vestibular Syndrome: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Study.
Topics: Adolescent; Adult; Aged; Betahistine; Double-Blind Method; Humans; Middle Aged; Nystagmus, Pathologi | 2023 |
Cinnarizine/betahistine combination vs. the respective monotherapies in acute peripheral vertigo: a randomized triple-blind placebo-controlled trial.
Topics: Adult; Betahistine; Calcium Channel Blockers; Cinnarizine; Drug Combinations; Female; Histamine Anta | 2019 |
Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferior
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betahistine; Cinnarizine; Dimenhydrinate; Double-Blind M | 2019 |
[A study of the efficacy and safety of a new modified-release betahistine formulation in the treatment of vestibular vertigo and Meniere's disease].
Topics: Betahistine; Double-Blind Method; Emotions; Humans; Meniere Disease; Vertigo | 2020 |
Randomized trial of betahistine mesilate tablets as augmentation for oxcarbazepine and carbamazepine in treating vestibular paroxysmia.
Topics: Anticonvulsants; Betahistine; Carbamazepine; Dose-Response Relationship, Drug; Drug Administration S | 2018 |
[Flunarizine in the prophylaxis of vestibular migraine:a randomized controlled trial].
Topics: Anticonvulsants; Betahistine; Flunarizine; Humans; Life Style; Migraine Disorders; Vertigo | 2016 |
Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial.
Topics: Acetaminophen; Adolescent; Adult; Aged; Betahistine; Calcium Channel Blockers; Disorders of Excessiv | 2014 |
Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial).
Topics: Adult; Aged; Aged, 80 and over; Betahistine; Dose-Response Relationship, Drug; Double-Blind Method; | 2016 |
A Two-Year Randomized Trial of Interventions to Decrease Stress Hormone Vasopressin Production in Patients with Meniere's Disease-A Pilot Study.
Topics: Adult; Aged; Betahistine; Disease Management; Drinking; Female; Follow-Up Studies; Hearing Loss; Hum | 2016 |
[Comparative assessment of results in cervical vertigo pharmacotherapy vs physiotherapy treatment].
Topics: Adult; Aged; Aged, 80 and over; Betahistine; Cervical Vertebrae; Female; Humans; Male; Middle Aged; | 2007 |
Treatment of vertebrobasilar insufficiency--associated vertigo with a fixed combination of cinnarizine and dimenhydrinate.
Topics: Adult; Betahistine; Calcium Channel Blockers; Cinnarizine; Dimenhydrinate; Double-Blind Method; Drug | 2008 |
Efficacy of a home-based exercise program on benign paroxysmal positional vertigo compared with betahistine.
Topics: Betahistine; Dose-Response Relationship, Drug; Electronystagmography; Exercise Therapy; Eye Movement | 2008 |
Effect of treatment with betahistine dihydrochloride on the postural stability in patients with different duration of benign paroxysmal positional vertigo.
Topics: Adult; Betahistine; Humans; Postural Balance; Posture; Vasodilator Agents; Vertigo; Vestibule, Labyr | 2010 |
Effects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anxiety; Betahistine; Body Weight; Depression; Health St | 2010 |
The effects of betahistine in addition to epley maneuver in posterior canal benign paroxysmal positional vertigo.
Topics: Administration, Oral; Adolescent; Adult; Aged; Benign Paroxysmal Positional Vertigo; Betahistine; Do | 2012 |
Effect of transtympanic low-pressure therapy in patients with unilateral Menière's disease unresponsive to betahistine: a randomised, placebo-controlled, double-blinded, clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Audiometry, Pure-Tone; Betahistine; Caloric Tests; Double-Blind Meth | 2012 |
Benign paroxysmal positional vertigo (BPPV): influence of pharmacotherapy and rehabilitation therapy on patients' recovery rate and life quality.
Topics: Adult; Aged; Aged, 80 and over; Benign Paroxysmal Positional Vertigo; Betahistine; Female; Histamine | 2012 |
Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo.
Topics: Administration, Oral; Adult; Betahistine; Dose-Response Relationship, Drug; Double-Blind Method; Dru | 2003 |
[Comparative efficacy of betaserc and cinnarizine of vertigo in patients with migraine].
Topics: Adult; Analysis of Variance; Betahistine; Cinnarizine; Female; Histamine Agents; Humans; Male; Middl | 2003 |
Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo.
Topics: Adult; Aged; Betahistine; Double-Blind Method; Drug Administration Schedule; Female; Flunarizine; Hi | 2003 |
Fixed combination of cinnarizine and dimenhydrinate versus betahistine dimesylate in the treatment of Ménière's disease: a randomized, double-blind, parallel group clinical study.
Topics: Adult; Aged; Betahistine; Cinnarizine; Dimenhydrinate; Double-Blind Method; Drug Combinations; Femal | 2002 |
[Current approaches to the treatment of vertigo in children].
Topics: Adolescent; Betahistine; Child; Cinnarizine; Female; Humans; Male; Treatment Outcome; Vertebrobasila | 2003 |
[A clinical study on the effect of Yinxing Damo combined with betahistine hydrochloride injection on vertebral basilar artery ischemic vertigo].
Topics: Adult; Aged; Aged, 80 and over; Betahistine; Drugs, Chinese Herbal; Female; Hemorheology; Humans; In | 2005 |
[Assessment of betahistine dihydrochloride effectiveness in the treatment of vertigo of a different aetiology based on videonystagmography test results].
Topics: Betahistine; Double-Blind Method; Electronystagmography; Evaluation Studies as Topic; Female; Humans | 2006 |
[Clinical effectiveness of betahistine in monotherapy of vertigo for different etiology].
Topics: Adult; Aged; Aged, 80 and over; Betahistine; Dose-Response Relationship, Drug; Female; Humans; Male; | 2006 |
[Forms of vestibular vertigo. Evaluation of a clinical trial (phase IV) of Ribrain in 3550 patients].
Topics: Adolescent; Adult; Aged; Betahistine; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; P | 1983 |
Betahistine dihydrochloride in the treatment of vertigo of peripheral vestibular origin. A double-blind placebo-controlled study.
Topics: Activities of Daily Living; Betahistine; Clinical Trials as Topic; Double-Blind Method; Female; Huma | 1984 |
Betahistine in peripheral vertigo: a double-blind, placebo-controlled, cross-over study of Serc versus placebo.
Topics: Adult; Betahistine; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged | 1981 |
[Long-term therapy of Ménière's disease. Comparison of the effects of betahistine dihydrochloride and hydrochlorothiazide].
Topics: Audiometry, Pure-Tone; Betahistine; Clinical Trials as Topic; Double-Blind Method; Humans; Hydrochlo | 1982 |
Vestibular training for benign paroxysmal positional vertigo. Its efficacy in comparison with antivertigo drugs.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Betahistine; Combined Modality Therapy; Female; Humans; | 1994 |
Vestibular training for acute unilateral vestibular disturbances: its efficacy in comparison with antivertigo drug.
Topics: Adult; Ataxia; Betahistine; Female; Humans; Male; Middle Aged; Severity of Illness Index; Vertigo | 1996 |
Dose-dependent effect of betahistine on the vestibulo-ocular reflex: a double-blind, placebo controlled study in patients with paroxysmal vertigo.
Topics: Adolescent; Adult; Betahistine; Dose-Response Relationship, Drug; Double-Blind Method; Head; Histami | 1997 |
Homeopathic vs conventional treatment of vertigo: a randomized double-blind controlled clinical study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betahistine; Double-Blind Method; Female; Homeopathy; Hu | 1998 |
[Treatment of vertigo with betaserk in patients with vascular and traumatic cerebral injuries].
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Basilar Artery; Betahistine; Brain Injuries; Evoked P | 1998 |
Pre and post betahistine therapy 99m Tc - HMPAO brain spect studies in patients with vertigo.
Topics: Betahistine; Female; Humans; Male; Middle Aged; Radiopharmaceuticals; Technetium Tc 99m Exametazime; | 2000 |
Betahistine in Ménière's disease.
Topics: Adult; Audiometry; Betahistine; Clinical Trials as Topic; Deafness; Female; Humans; Male; Meniere Di | 1976 |
Betahistine hydrochloride in Méniére's disease.
Topics: Adult; Betahistine; Clinical Trials as Topic; Female; Humans; Male; Meniere Disease; Middle Aged; Py | 1976 |
[Betahistidine hydrochloride in the treatment of vertebro-basilar insufficiency].
Topics: Aged; Basilar Artery; Betahistine; Cerebrovascular Disorders; Drug Evaluation; Female; Humans; Male; | 1975 |
[Trimetazidine versus betahistine in vestibular vertigo. A double blind study].
Topics: Adult; Analysis of Variance; Audiometry; Betahistine; Double-Blind Method; Female; Humans; Labyrinth | 1990 |
Flunarizine and betahistine. Two different therapeutic approaches in vertigo compared in a double-blind study.
Topics: Adult; Aged; Betahistine; Clinical Trials as Topic; Double-Blind Method; Female; Flunarizine; Humans | 1988 |
A double-blind crossover study comparing betahistine and cinnarizine in the treatment of recurrent vertigo in patients in general practice.
Topics: Aged; Betahistine; Cinnarizine; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Middle A | 1986 |
Ménière's disease.
Topics: Betahistine; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Meniere Disease; Nausea; Placebos; | 1967 |
[Clinical experience with beta-histine].
Topics: Adult; Amine Oxidase (Copper-Containing); Betahistine; Clinical Trials as Topic; Ethylamines; Female | 1969 |
60 other studies available for betahistine and Central Nervous System Origin Vertigo
| Article | Year |
|---|---|
Evaluation of changes in endolymphatic hydrops volume after medical treatments for Meniere's disease using 3D magnetic resonance imaging.
Topics: Betahistine; Endolymphatic Hydrops; Humans; Magnetic Resonance Imaging; Meniere Disease; Retrospecti | 2023 |
Conservative Treatment Possibilities of Ménière Disease, Involving Vertigo Diaries.
Topics: Betahistine; Conservative Treatment; Drug Therapy, Combination; Female; Humans; Male; Medical Record | 2021 |
The Challenges of Studying Peripheral Vestibular Vertigo.
Topics: Betahistine; Cinnarizine; Dimenhydrinate; Double-Blind Method; Humans; Prospective Studies; Vertigo | 2020 |
Authors' Reply to "The Challenges of Studying Peripheral Vestibular Vertigo".
Topics: Betahistine; Cinnarizine; Dimenhydrinate; Double-Blind Method; Humans; Prospective Studies; Vertigo | 2020 |
Comment on "Is cinnarizine/betahistine combination superior to respective monotherapies in treatment of vertigo? A randomized triple-blind placebo-controlled trial".
Topics: Betahistine; Cinnarizine; Histamine H1 Antagonists; Humans; Vertigo | 2020 |
Is cinnarizine/betahistine combination superior to respective monotherapies in treatment of vertigo? Comment on a randomized triple-blind placebo-controlled trial.
Topics: Betahistine; Cinnarizine; Histamine H1 Antagonists; Humans; Vertigo | 2020 |
Clinical therapeutic effects of gastrodin in combination with betahistine on vertigo: A protocol for systematic review and meta-analysis.
Topics: Benzyl Alcohols; Betahistine; China; Drug Therapy, Combination; Glucosides; Humans; Meta-Analysis as | 2021 |
Effectiveness of intratympanic dexamethasone for the treatment of vertigo attacks in patients with Ménière's disease compared with betahistine pharmacotherapy.
Topics: Betahistine; Dexamethasone; Humans; Meniere Disease; Prospective Studies; Vertigo | 2021 |
Acute Pisa syndrome secondary to betahistine treatment in a patient with mild cognitive impairment.
Topics: Aged; Betahistine; Cognitive Dysfunction; Dystonic Disorders; Female; Humans; Hydrocephalus, Normal | 2018 |
Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: The VIRTUOSO study.
Topics: Adult; Aged; Betahistine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Prospecti | 2017 |
Efficacy of Betahistine by Patient-Reported Outcomes and its Tolerability Profile in Indian Patients with Vestibular Vertigo.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betahistine; Female; Follow-Up Studies; Humans; Male; Mi | 2017 |
Population-Based Study on the Epidemiology of Ménière's Disease.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Anxiety; Betahistine; Case-Control Studies; Comorbidity; | 2017 |
Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.
Topics: Adult; Aged; Aged, 80 and over; Betahistine; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2018 |
Patient Perceptions of Effectiveness in Treatments for Menière's Disease: a National Survey in Italy.
Topics: Absenteeism; Anti-Bacterial Agents; Betahistine; Cross-Sectional Studies; Diet Therapy; Diuretics; F | 2019 |
Betahistine in the Treatment of Peripheral Vestibular Vertigo: Results of a Real-Life Study in Primary Care.
Topics: Adult; Aged; Benign Paroxysmal Positional Vertigo; Betahistine; Colombia; Female; Humans; Male; Midd | 2020 |
[Characteristics and drug analysis associated with vertigo disease in real world].
Topics: Adolescent; Adult; Aged; Benzyl Alcohols; Betahistine; Diagnosis, Differential; Female; Glucosides; | 2014 |
Betahistine plus piracetam dual therapy versus betahistine monotherapy for peripheral vestibular vertigo: a confounder-corrected subanalysis of the OSVaLD study.
Topics: Adult; Aged; Betahistine; Dizziness; Female; Humans; Male; Middle Aged; Odds Ratio; Piracetam; Vasod | 2015 |
Betahistine: hallucinations?
Topics: Betahistine; Hallucinations; Histamine Agonists; Humans; Vertigo | 2015 |
Efficacy and acceptability of oxcarbazepine vs. carbamazepine with betahistine mesilate tablets in treating vestibular paroxysmia: a retrospective review.
Topics: Aged; Betahistine; Carbamazepine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Oxca | 2016 |
Topics: Benign Paroxysmal Positional Vertigo; Betahistine; Humans; Prevalence; Randomized Controlled Trials | 2016 |
Bayesian model selection techniques as decision support for shaping a statistical analysis plan of a clinical trial: an example from a vertigo phase III study with longitudinal count data as primary endpoint.
Topics: Bayes Theorem; Betahistine; Clinical Trials as Topic; Data Interpretation, Statistical; Decision Sup | 2012 |
[Vertigo: patient management tactics].
Topics: Adult; Betahistine; Diagnosis, Differential; Dizziness; Female; Histamine Agonists; Humans; Male; Tr | 2012 |
[Treatment of vestibular vertigo and Ménière syndrome in outpatient clinics].
Topics: Adult; Aged; Ambulatory Care Facilities; Betahistine; Combined Modality Therapy; Exercise; Female; H | 2012 |
[A variant of monotherapy in vertigo and subjective noise in the ears].
Topics: Adult; Aged; Betahistine; Female; Hearing Loss, Sensorineural; Histamine Agonists; Humans; Male; Mid | 2002 |
Homeopathic vs conventional treatment of vertigo.
Topics: Betahistine; Drug Approval; Drug Combinations; Humans; Materia Medica; Minerals; Phytotherapy; Picro | 2003 |
[Betaserc treatment of psychogenic vertigo].
Topics: Adult; Affective Disorders, Psychotic; Betahistine; Eye Movements; Female; Histamine Agents; Humans; | 2004 |
[A use of betaserc in ataxic syndromes].
Topics: Aged; Aged, 80 and over; Ataxia; Betahistine; Cerebellar Ataxia; Female; Histamine Agonists; Humans; | 2004 |
Investigation of Betaserc in auditory and vestibular disturbances.
Topics: Adult; Audiometry; Auditory Diseases, Central; Auditory Pathways; Betahistine; Dizziness; Electronys | 2004 |
[Betaserc and improvement of life quality in war veterans].
Topics: Adult; Betahistine; Headache; Histamine Agonists; Humans; Male; Quality of Life; Russia; Sleep Wake | 2005 |
[Cerebral hemodynamics and statokinetic functions in patients with vertebral basilar vascular insufficiency].
Topics: Adult; Betahistine; Cerebrovascular Circulation; Chronic Disease; Humans; Middle Aged; Postural Bala | 2004 |
Benign paroxysmal positional vertigo: a study of two manoeuvres with and without betahistine.
Topics: Adult; Age Factors; Aged; Betahistine; Female; Humans; Male; Middle Aged; Posture; Prospective Studi | 2005 |
[Epidemiology, clinical features and betaserc therapy of vertigo in initial and reversible cerebrovascular pathology].
Topics: Adult; Aged; Betahistine; Brain; Cerebrovascular Circulation; Evoked Potentials, Auditory; Female; H | 2005 |
[Vertigo attacks -- current therapy].
Topics: Acetazolamide; Adult; Aged; Betahistine; Dexamethasone; Ear, Middle; Gentamicins; Humans; Injections | 2005 |
[Clinico-neurological and stabilometric analysis of betahistine (betaserc) efficacy in the patients with vertigo in the rehabilitation period of ischemic stroke].
Topics: Aged; Antihypertensive Agents; Betahistine; Biofeedback, Psychology; Drug Therapy, Combination; Fema | 2005 |
Betahistine: a retrospective synopsis of safety data.
Topics: Adverse Drug Reaction Reporting Systems; Betahistine; Drug Interactions; Humans; Meniere Disease; Pr | 2006 |
[Assessment of betahistine dihydrochloride effectiveness in the treatment of disturbance of balance system, based on analysis of doctors and patients questionnaires results].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Betahistine; Data Collection; Dizziness; Fe | 2006 |
[Vestibular neuritis--a case description].
Topics: Adolescent; Anti-Anxiety Agents; Benzodiazepines; Betahistine; Glucocorticoids; Humans; Male; Nausea | 2007 |
Patient baseline characteristics in an open-label multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD study.
Topics: Adult; Betahistine; Female; Humans; Male; Middle Aged; Recurrence; Treatment Outcome; Vasodilator Ag | 2007 |
Complications of treatment of peripheral vertigo.
Topics: Aminoglycosides; Anti-Anxiety Agents; Antiemetics; Betahistine; Diuretics; Humans; Meniere Disease; | 1984 |
[Clinical experiences with betahistine].
Topics: Adult; Aged; Betahistine; Cochlea; Female; Hearing Loss; Humans; Labyrinth Diseases; Male; Middle Ag | 1983 |
[Betahistinedimesilate in the therapy of vertigo states in multiple sclerosis].
Topics: Adult; Aged; Betahistine; Female; Headache; Humans; Male; Middle Aged; Multiple Sclerosis; Pyridines | 1983 |
Antivertigo agents. I. Structure-activity relationships of 2-(2-aminoethyl)pyridines.
Topics: Animals; Betahistine; Blood Pressure; Cats; Dogs; Female; Guinea Pigs; In Vitro Techniques; Male; Mu | 1984 |
Drug treatment of vertigo and Ménière's disease. Cinnarizine and betahistine.
Topics: Betahistine; Cinnarizine; Humans; Meniere Disease; Piperazines; Pyridines; Vertigo | 1981 |
[Treatment of Menière's disease in general practice].
Topics: Adult; Aged; Betahistine; Drug Evaluation; Female; Hearing Loss; Humans; Male; Meniere Disease; Midd | 1980 |
Effects of histamine and betahistine on rat medial vestibular nucleus neurones: possible mechanism of action of anti-histaminergic drugs in vertigo and motion sickness.
Topics: Animals; Betahistine; Dose-Response Relationship, Drug; Histamine; Motion Sickness; Ranitidine; Rats | 1995 |
Postmarketing study of the use of flunarizine in vestibular vertigo and in migraine.
Topics: Basal Ganglia Diseases; Betahistine; Cohort Studies; Depression; Female; Flunarizine; Histamine H1 A | 1996 |
Nonpigmenting fixed drug eruption: a new case due to betahistine.
Topics: Betahistine; Drug Eruptions; Erythema; Female; Histamine Agonists; Humans; Hypersensitivity, Delayed | 1996 |
[Acute dystonia secondary to treatment with betahistine].
Topics: Acute Disease; Adult; Betahistine; Dystonia; Female; Humans; Trismus; Vasodilator Agents; Vertigo | 2000 |
Betahistine in the treatment of vertigo. History and clinical implications of recent pharmacological researches.
Topics: Betahistine; History, 20th Century; Meniere Disease; Research; Vasodilator Agents; Vertigo | 2001 |
[Drug information. Therapeutic main group: agents for the treatment of dizziness--betahistine].
Topics: Betahistine; Humans; Meniere Disease; Pyridines; Vertigo | 1979 |
[Drug information. Therapeutic main group: agents for the treatment of vertigo. Behahistine (Betaserc)].
Topics: Betahistine; Humans; Meniere Disease; Pyridines; Vertigo | 1979 |
[Betahistine treatment of Menière's disease (author's transl)].
Topics: Betahistine; Deafness; Drug Evaluation; Female; Humans; Male; Meniere Disease; Pyridines; Tinnitus; | 1978 |
[Therapy of vertigo].
Topics: Betahistine; Humans; Meniere Disease; Surveys and Questionnaires; Thiethylperazine; Vertigo | 1975 |
Effects of anti-vertigo drugs on medial vestibular nucleus neurons activated by horizontal rotation.
Topics: Animals; Betahistine; Cats; Diphenhydramine; Glutamates; Glutamic Acid; Iontophoresis; Male; Neurons | 1991 |
Treatment of acute vestibular vertigo.
Topics: Acute Disease; Betahistine; Humans; Meniere Disease; Vertigo | 1991 |
[Trimetazidine versus betahistine in Ménière's disease. A double blind method].
Topics: Adolescent; Adult; Aged; Audiometry; Betahistine; Double-Blind Method; Female; Humans; Male; Meniere | 1990 |
Effect of betahistine dihydrochloride compared with cinnarizine on induced vestibular nystagmus.
Topics: Adult; Betahistine; Cinnarizine; Electronystagmography; Female; Humans; Male; Nystagmus, Physiologic | 1989 |
Otogenic vertigo--an occupational hazard.
Topics: Betahistine; Humans; Meniere Disease; Occupational Medicine; Vertigo | 1967 |
An agent for the amelioration of vertigo in Ménière's syndrome. Betahistine hydrochloride (Serc).
Topics: Amine Oxidase (Copper-Containing); Betahistine; Ethylamines; Meniere Disease; Pyridines; Vertigo | 1968 |
[Clinical use of Bethahistine mesylate].
Topics: Adolescent; Adult; Aged; Amine Oxidase (Copper-Containing); Betahistine; Child; Ethylamines; Female; | 1969 |